Psyence Group

Psyence Group is a life sciences biotechnology company that is pioneering the use of natural psychedelics in mental health and wellbeing. It is pleased to announce that it has received Phase IIa clinical trial approval from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK regulatory body equivalent to Health Canada and the US FDA. Psyence Group is developing appropriate natural psilocybin drug development and treatment protocols, with a focus on palliative care, where there is currently a lack of treatments for adjustment disorders associated with terminal diagnoses. While antidepressant therapies may be effective, they can also reduce quality of life. Research shows that natural psilocybin-based drugs are safe and effective and can improve quality of life.